{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:40:30Z","timestamp":1780605630082,"version":"3.54.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,28]]},"DOI":"10.7759\/cureus.86902","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T10:24:28Z","timestamp":1751106268000},"source":"Crossref","is-referenced-by-count":1,"title":["Fatal Toxic Megacolon Following Nivolumab and Ipilimumab Therapy in Metastatic Melanoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Hibiki","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Katsurada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ujiie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30700-9.","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi FS","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, et al.. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018, 19:1480-1492. 10.1016\/S1470-2045(18)30700-9.","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2023.10.009. eCollection 2024.","article-title":"A case of successful treatment against toxic megacolon associated with immune checkpoint inhibitor-induced colitis","volume":"3","author":"Ikeda S","year":"2023","unstructured":"Ikeda S, Watanabe D, Kodama Y. A case of successful treatment against toxic megacolon associated with immune checkpoint inhibitor-induced colitis. Gastro Hep Adv. 2023, 3:58-9. 10.1016\/j.gastha.2023.10.009. eCollection 2024.","journal-title":"Gastro Hep Adv"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang L","year":"2021","unstructured":"Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, Ma X. Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol. 2021, 12:800879. 10.3389\/fimmu.2021.800879","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116999","article-title":"irAE-colitis induced by CTLA-4 and PD-1 blocking were ameliorated by TNF blocking and modulation of gut microbial","volume":"177","author":"Ye R","year":"2024","unstructured":"Ye R, Zheng H, Yang D, et al.. irAE-colitis induced by CTLA-4 and PD-1 blocking were ameliorated by TNF blocking and modulation of gut microbial. Biomed Pharmacother. 2024, 177:116999. 10.1016\/j.biopha.2024.116999","journal-title":"Biomed Pharmacother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S200760","article-title":"Toxic megacolon: background, pathophysiology, management challenges and solutions","volume":"13","author":"Desai J","year":"2020","unstructured":"Desai J, Elnaggar M, Hanfy AA, Doshi R. Toxic megacolon: background, pathophysiology, management challenges and solutions. Clin Exp Gastroenterol. 2020, 13:203-10. 10.2147\/CEG.S200760","journal-title":"Clin Exp Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/354644-fatal-toxic-megacolon-following-nivolumab-and-ipilimumab-therapy-in-metastatic-melanoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T10:24:28Z","timestamp":1751106268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/354644-fatal-toxic-megacolon-following-nivolumab-and-ipilimumab-therapy-in-metastatic-melanoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.86902","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,28]]}}}